<DOC>
	<DOC>NCT01152645</DOC>
	<brief_summary>A phase II open-label study with ARQ 197 administered orally and twice daily as monotherapy in patients with previously treated advanced/recurrent gastric cancer. The primary endpoint is disease control and the secondary efficacy endpoints include antitumor effect (tumor response), progression-free survival and overall survival. The pharmacokinetic profile and the safety profile are also evaluated.</brief_summary>
	<brief_title>Study of ARQ 197 Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Japanese or Korean with voluntary written informed consent for study participation A histologically or cytologically confirmed advanced/recurrent gastric cancer One or two prior chemotherapy regimens for advanced/recurrent gastric cancer At least one measurable lesion ECOG performance status of 0 or 1 Life expectancy â‰¥3 months Surgery for cancer within 4 weeks prior to the first dose of ARQ 197 Confirmed other tumors than gastric cancer within 5 years prior to the first dose of ARQ 197 Anticancer chemotherapy, hormone therapy, radiotherapy or immunotherapy within 2 weeks prior to the first dose of ARQ 197 Positive for HIV antibody Known symptomatic brain metastasis Gastrointestinal disorders that could interfere with the absorption of ARQ 197 or operation history for gastrointestinal disorders Uncontrolled concomitant disease Patients who wish to have a child and who would not agree to use contraceptive measures Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced/recurrent gastric cancer</keyword>
</DOC>